izpis_h1_title_alt

Deuterated drugs and biomarkers in the COVID-19 pandemic
ID Jansen-van Vuuren, Ross D. (Author), ID Jedlovčnik, Luka (Author), ID Košmrlj, Janez (Author), ID Massey, Thomas E. (Author), ID Derdau, Volker (Author)

.pdfPDF - Presentation file, Download (3,59 MB)
MD5: F23C1C6747856A5B6139D594A055AB73
URLURL - Source URL, Visit https://pubs.acs.org/doi/10.1021/acsomega.2c04160 This link opens in a new window

Abstract
Coronavirus disease 2019 (COVID-19) is a highly contagious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Initially identified in Wuhan (China) in December 2019, COVID-19 rapidly spread globally, resulting in the COVID-19 pandemic. Carriers of the SARS-CoV-2 can experience symptoms ranging from mild to severe (or no symptoms whatsoever). Although vaccination provides extra immunity toward SARS-CoV-2, there has been an urgent need to develop treatments for COVID-19 to alleviate symptoms for carriers of the disease. In seeking a potential treatment, deuterated compounds have played a critical role either as therapeutic agents or as internal MS standards for studying the pharmacological properties of new drugs by quantifying the parent compounds and metabolites. We have identified >70 examples of deuterium-labeled compounds associated with treatment of COVID-19. Of these, we found 9 repurposed drugs and >20 novel drugs studied for potential therapeutic roles along with a total of 38 compounds (drugs, biomarkers, and lipids) explored as internal mass spectrometry standards. This review details the synthetic pathways and modes of action of these compounds (if known), and a brief analysis of each study.

Language:English
Keywords:COVID-19, hydrogen isotopes, inhibitors, metabolism, pharmaceuticals
Work type:Article
Typology:1.02 - Review Article
Organization:FKKT - Faculty of Chemistry and Chemical Technology
Publication status:Published
Publication version:Version of Record
Year:2022
Number of pages:Str. 41840-41858
Numbering:Vol. 7, iss. 46
PID:20.500.12556/RUL-144314 This link opens in a new window
UDC:547.8:546.11
ISSN on article:2470-1343
DOI:10.1021/acsomega.2c04160 This link opens in a new window
COBISS.SI-ID:131181827 This link opens in a new window
Publication date in RUL:14.02.2023
Views:588
Downloads:446
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:ACS omega
Shortened title:ACS omega
Publisher:American Chemical Society
ISSN:2470-1343
COBISS.SI-ID:525873945 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:COVID-19, izotopi vodika, inhibitorji, presnova, zdravila

Projects

Funder:Other - Other funder or multiple funders
Funding programme:Queen’s University, Rapid Response Funding

Funder:Other - Other funder or multiple funders
Funding programme:Southeastern Ontario Academic Medical Organization

Funder:EC - European Commission
Funding programme:H2020
Project number:945380
Name:EUTOPIA-Science and Innovation Fellowships
Acronym:EUTOPIA-SIF

Funder:ARRS - Slovenian Research Agency
Project number:P1-0230
Name:Organska kemija: sinteza, struktura in aplikacija

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back